酪氨酸激酶
ROS1型
肺癌
癌症研究
医学
癌症
内科学
化学
腺癌
受体
作者
Xinmin Zhao,Xin Zhang,Hanlin Chen,Hairong Bao,Xianghua Wu,Huijie Wang,Hua Bao,Jiaohui Pang,Sha Wang,Jialei Wang
出处
期刊：Clinical Chemistry
[American Association for Clinical Chemistry]
日期：2024-02-28
卷期号：70 (4): 629-641
被引量：5
标识
DOI：10.1093/clinchem/hvae008
摘要
ROS1 fusion-positive (ROS1+) nonsmall cell lung cancer (NSCLC) patients are highly sensitive to tyrosine kinase inhibitor (TKI) treatments. However, acquired TKI resistance remains the major hurdle preventing patients from experiencing prolonged benefits.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
LaTeXer
FIN
Sandy
Rondab
Magali
pcr163
Emma
GingerF
jyy
cc
轻舟
aldehyde
scm
Hayat
可爱打工霖
bxxxxx
从容芮
lily
eric888
linkman
皖公网安备34019202002308
